載入...
Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
OBJECTIVE: Romidepsin (FK228) was recently approved by the FDA for the treatment of cutaneous and peripheral T cell lymphoma. We have shown in vitro efficacy of FK228 in ovarian cancer. Here, our goal was to evaluate FK228 combined with cisplatin in ovarian cancer in vitro and in vivo. METHODS: Ovar...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3541411/ https://ncbi.nlm.nih.gov/pubmed/23010348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.09.016 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|